HPV Vaccination Recommendations for Pre‑Teen Females

Target Age Groups

Routine HPV vaccination is recommended for females at ages 11–12 years to ensure protection before potential exposure through sexual activity. Strong recommendation. 1, 2, 3
Initiation at ages 9–10 years is endorsed by the American Academy of Pediatrics and the American Cancer Society, offering higher series completion rates (≈ 97 % vs 78 % when started later) and stronger immune responses. Strong recommendation. 4
Catch‑up vaccination is advised for females aged 13–26 years who have not completed the series, although effectiveness declines with increasing age because of higher likelihood of prior HPV exposure. Moderate recommendation. 1, 2, 3

The vaccine is administered as a 0.5 mL intramuscular injection, preferably in the deltoid muscle. Strong recommendation. 2, 3
HPV vaccine may be given concurrently with other age‑appropriate vaccines (e.g., Tdap, meningococcal conjugate) during the same visit, using separate syringes and different anatomic sites. Strong recommendation. 1, 2, 3
If the vaccination series is interrupted, it does not need to be restarted; remaining doses should be administered while respecting the minimum interval requirements. Strong recommendation. 2, 3

Females with abnormal or equivocal Pap test results should still receive HPV vaccination. Strong recommendation. 1, 6
Immunocompromised individuals (e.g., HIV infection or receiving immunosuppressive therapy) should follow a 3‑dose schedule regardless of the age at initiation. Strong recommendation. 1, 6
Breastfeeding is not a contraindication to HPV vaccination. Strong recommendation. 1, 6
Prior sexual activity does not preclude vaccination; most individuals have not been infected with all vaccine‑covered HPV types, and no pre‑vaccination testing (Pap, HPV DNA, or antibody) is required. Strong recommendation. 2, 3

Absolute contraindication: a history of immediate hypersensitivity to yeast or any vaccine component. Strong recommendation. 1, 6, 7
HPV vaccination is not recommended during pregnancy; if pregnancy occurs during the series, remaining doses should be postponed until after delivery. Strong recommendation. 1, 6, 7
Vaccination should be deferred in individuals with moderate or severe acute illness until recovery. Strong recommendation. 6, 7
To prevent syncope, recipients should remain seated or supine for at least 15 minutes after injection. Strong recommendation. 6, 7

Do not order pre‑vaccination screening tests (Pap smear, HPV DNA, or antibody testing); these add cost and delay without clinical benefit. Strong recommendation. 2, 3
Do not defer vaccination based on sexual history; even sexually active individuals benefit from protection against HPV types they have not yet acquired. Strong recommendation. 2, 3, 8
Vaccination does not eliminate the need for routine cervical cancer screening; vaccinated females should continue age‑appropriate Pap testing because the vaccine covers ≈ 70 % of oncogenic HPV types. Strong recommendation. 1, 3
Recommendations for HPV vaccination should be as strong as those for other adolescent vaccines (Tdap, meningococcal) to maximize uptake. Strong recommendation. 4

The highest antibody responses are observed in individuals aged 9–15 years, supporting early vaccination. Strong evidence. 1, 7
Administering the vaccine before sexual debut maximizes effectiveness, as protection is greatest prior to exposure. Strong evidence. 1, 8
Clinical studies demonstrate at least 5 years of sustained protection without waning. Strong evidence. 1, 7
Aligning vaccination with routine adolescent health visits (e.g., 11‑year well‑child visit) facilitates high coverage. Strong evidence. 1, 4
Vaccination prevents cervical cancer, other anogenital cancers, oropharyngeal cancers, and genital warts. Strong evidence. 1, 4, 8